Market Overview

UPDATE: Auxilium Posts Upbeat Q3 Profit

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

Auxilium Pharmaceuticals (NASDAQ: AUXL) reported an upbeat third-quarter profit and narrowed its revenue outlook for the full year.

Auxilium now projects full-year revenue of $370 million to $401 million, versus its prior forecast of $363 million to $405 million.

Auxilium posted a quarterly net loss of $28.9 million, or $0.59 per share, versus a year-ago loss of $10.5 million, or $0.21 per share. Excluding items, it earned $0.17 per share.

Its net revenue rose 52% to $108.1 million. However, analysts were expecting a profit of $0.15 per share on revenue of $103.7 million.

Auxilium shares gained 5.55% to $18.25 in pre-market trading.

Posted-In: profitEarnings News Guidance


Related Articles (AUXL)

View Comments and Join the Discussion!

Partner Center